{"id":"https://openalex.org/W2019089983","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","title":"Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.","display_name":"Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2019089983","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","mag":"2019089983"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.sabcs-09-5114","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Baselga","raw_affiliation_strings":["1Vall d'Hebron University Hospital, Spain","Vall d'Hebron University Hospital, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vall d'Hebron University Hospital, Spain","institution_ids":["https://openalex.org/I4210127641"]},{"raw_affiliation_string":"Vall d'Hebron University Hospital, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051629490","display_name":"Javier Cort\u00e9s","orcid":"https://orcid.org/0000-0001-7623-1583","observed_orcids":["https://orcid.org/0000-0001-7623-1583"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Cortes","raw_affiliation_strings":["1Vall d'Hebron University Hospital, Spain","Vall d'Hebron University Hospital, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vall d'Hebron University Hospital, Spain","institution_ids":["https://openalex.org/I4210127641"]},{"raw_affiliation_string":"Vall d'Hebron University Hospital, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012804079","display_name":"P. Fumoleau","orcid":"https://orcid.org/0000-0002-2912-2170","observed_orcids":["https://orcid.org/0000-0002-2912-2170"]},"institutions":[{"id":"https://openalex.org/I4210094685","display_name":"Centre Georges Fran\u00e7ois Leclerc","ror":"https://ror.org/00pjqzf38","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210094685","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"P. Fumoleau","raw_affiliation_strings":["2Centre Georges-Franc\u0327ois-Leclerc, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Centre Georges-Franc\u0327ois-Leclerc, France","institution_ids":["https://openalex.org/I4210094685"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102977157","display_name":"Teresa M. Petrella","orcid":"https://orcid.org/0000-0002-2933-1861","observed_orcids":["https://orcid.org/0000-0002-2933-1861"]},"institutions":[{"id":"https://openalex.org/I1323843004","display_name":"Sunnybrook Health Science Centre","ror":"https://ror.org/03wefcv03","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"T. Petrella","raw_affiliation_strings":["3Toronto-Sunnybrook Cancer Centre, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Toronto-Sunnybrook Cancer Centre, Canada","institution_ids":["https://openalex.org/I1323843004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067468792","display_name":"Karen A. Gelmon","orcid":"https://orcid.org/0000-0003-4111-2757","observed_orcids":["https://orcid.org/0000-0003-4111-2757"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"K. Gelmon","raw_affiliation_strings":["4British Columbia Cancer Agency, BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4British Columbia Cancer Agency, BC, Canada","institution_ids":["https://openalex.org/I1289530486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023572972","display_name":"Savita Verma","orcid":"https://orcid.org/0000-0002-1286-8259","observed_orcids":["https://orcid.org/0000-0002-1286-8259"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Verma","raw_affiliation_strings":["5Ottawa Regional Cancer Center, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Ottawa Regional Cancer Center, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044903892","display_name":"Xavier B. Pivot","orcid":"https://orcid.org/0000-0003-3689-5013","observed_orcids":["https://orcid.org/0000-0003-3689-5013"]},"institutions":[{"id":"https://openalex.org/I4210087978","display_name":"Centre Hospitalier Universitaire de Besan\u00e7on","ror":"https://ror.org/0084te143","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210087978"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"X. Pivot","raw_affiliation_strings":["6CHU Jean Minjoz, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6CHU Jean Minjoz, France","institution_ids":["https://openalex.org/I4210087978"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108548401","display_name":"G. A. Ross","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Ross","raw_affiliation_strings":["7Roche Products Limited, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Roche Products Limited, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053167365","display_name":"Tania Szado","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Szado","raw_affiliation_strings":["7Roche Products Limited, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Roche Products Limited, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058537459","display_name":"Luca Gianni","orcid":"https://orcid.org/0000-0002-2372-9625","observed_orcids":["https://orcid.org/0000-0002-2372-9625"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Gianni","raw_affiliation_strings":["8Oncologia Medica, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Oncologia Medica, Italy","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"69","issue":"24_Supplement","first_page":"5114","last_page":"5114"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/combination-antibody-therapy","display_name":"antibody combination therapy","score":0.6759999990463257},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8569999933242798},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.6690000295639038},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.3869999945163727},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.4650000035762787}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.9899290800094604},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9608732461929321},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8346978425979614},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6616916656494141},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5912909507751465},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5077963471412659},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.4907447099685669},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.48670557141304016},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45600900053977966},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3264670968055725}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.sabcs-09-5114","doi":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs-09-5114","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2244529370","https://openalex.org/W2161708183","https://openalex.org/W3000138523","https://openalex.org/W4248892246","https://openalex.org/W2321955050","https://openalex.org/W2343442843","https://openalex.org/W2098694743","https://openalex.org/W1833293810","https://openalex.org/W2009624280","https://openalex.org/W2050060618"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Pertuzumab,":[2],"a":[3,10,57,68,267,271],"fully":[4],"humanised":[5],"IgG1":[6],"monoclonal":[7],"antibody,":[8],"is":[9,209],"human":[11],"epidermal":[12],"growth":[13],"factor":[14],"receptor":[15,261],"2":[16,191,222],"(HER2)-dimerisation":[17],"inhibitor":[18],"directed":[19],"to":[20,28,41,66,73,91,104,179,270],"the":[21,29,75,152,181,210,230,254,260,275,301],"dimerisation":[22,283],"epitope":[23,273],"of":[24,71,77,126,154,177,187,195,253,257,266,303,305],"HER2":[25,285],"(trastuzumab":[26],"binds":[27],"juxta-membrane":[30],"epitope).":[31],"Pertuzumab":[32],"has":[33,216,232],"demonstrated":[34],"promising":[35],"activity":[36,76,200,215],"when":[37,79,221],"given":[38,80],"with":[39,43,54,97,162,236],"trastuzumab":[40,55,93,136,142],"patients":[42,72,113,133,161,169,220],"HER2-positive":[44],"metastatic":[45],"breast":[46],"cancer":[47],"(mBC)":[48],"which":[49,188,244],"had":[50,121,135,171],"progressed":[51,233],"during":[52,234],"therapy":[53,143,235],"in":[56,95,219,262],"2-step":[58],"Phase":[59],"II":[60],"study.1Methods:":[61],"The":[62,264,296],"protocol":[63],"was":[64,101],"amended":[65],"include":[67],"3rd":[69,87,118,124],"cohort":[70,88],"determine":[74],"pertuzumab":[78,98,105,145],"without":[81],"trastuzumab.2":[82],"Patients":[83,120],"recruited":[84,115],"into":[85,116],"this":[86,117,155,208,247],"were":[89,114,192],"allowed":[90],"have":[92,134,158,225],"re-introduced":[94,137],"combination":[96],"if":[99],"there":[100,157],"inadequate":[102],"response":[103,108,184],"alone":[106],"or":[107],"followed":[109],"by":[110],"relapse.Results:":[111],"Twenty-nine":[112],"cohort.":[119],"reached":[122],"their":[123],"line":[125],"treatment":[127],"for":[128,277],"mBC.":[129],"To":[130],"date,":[131],"15":[132,149],"after":[138,229],"disease":[139,231],"progression":[140],"on":[141,199],"and":[144,201,281,286,294,311,315],"monotherapy.":[146],"Among":[147],"these":[148],"patients,":[150],"at":[151,189],"time":[153,212],"analysis":[156],"been":[159,217,226],"3":[160],"confirmed":[163],"responses.":[164],"There":[165,240,308],"are":[166,241,309],"also":[167],"4":[168],"who":[170],"not":[172],"yet":[173],"undergone":[174],"8":[175],"cycles":[176],"assessments":[178],"reach":[180],"overall":[182],"best":[183],"end":[185],"point,":[186],"least":[190],"experiencing":[193],"stablisation":[194],"disease.":[196],"Updated":[197],"data":[198],"toxicity":[202],"will":[203],"be":[204],"presented.Conclusions:":[205],"We":[206],"believe":[207],"first":[211],"that":[213],"anti-tumour":[214],"reported":[218],"biological":[223,314],"agents":[224],"used":[227],"together":[228],"each":[237],"agent":[238],"alone.":[239],"several":[242],"mechanisms":[243],"might":[245,299],"explain":[246],"phenomenon.":[248],"Trastuzumab":[249],"prevents":[250,282],"proteolytic":[251],"cleavage":[252],"extracellular":[255],"domain":[256],"HER2,":[258],"keeping":[259],"situ.":[263],"addition":[265],"second":[268],"antibody":[269],"separate":[272],"increases":[274],"potential":[276],"antibody-dependent":[278],"cell-mediated":[279],"cytotoxicity":[280],"between":[284],"other":[287],"HER":[288],"family":[289],"members,":[290],"such":[291],"as":[292],"HER1":[293],"HER3.":[295],"combined":[297],"antibodies":[298],"increase":[300],"efficiency":[302],"inhibition":[304],"signal":[306],"transduction.":[307],"wide-ranging":[310],"potentially":[312],"significant":[313],"clinical":[316],"implications.":[317],"Citation":[318],"Information:":[319],"Cancer":[320],"Res":[321],"2009;69(24":[322],"Suppl):Abstract":[323],"nr":[324],"5114.":[325]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}